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Abstract 8 
P2X receptors are trimeric eukaryotic ATP-gated cation channels. Extracellular ATP - their 9 
physiological ligand - is released as a neurotransmitter and in conditions of cell damage such as 10 
inflammation, and substantial evidence implicates P2X receptors in diseases including neuropathic 11 
pain, cancer and arthritis. In 2009, the first P2X crystal structure, Danio rerio P2X4 in the apo- state, 12 
was published, and this was followed in 2012 by the ATP-bound structure. These structures 13 
transformed our understanding of the conformational changes induced by ATP binding and the 14 
mechanism of ligand specificity, and enabled homology modelling of mammalian P2X receptors for 15 
ligand docking and rational design of receptor modulators. P2X receptors are attractive drug targets, 16 
and a wide array of potent, subtype-selective modulators (mostly antagonists) have been developed. 17 
In 2016, crystal structures of human P2X3 in complex with the competitive antagonists TNP-ATP 18 
and A-317491, and Ailuropoda melanoleuca P2X7 in complex with a series of allosteric antagonists 19 
were published, giving fascinating insights into the mechanism of channel antagonism. In this article 20 
we not only summarize current understanding of small-molecule modulator binding at P2X receptors, 21 
but also use this information in combination with previously published structure-function data and 22 
molecular docking experiments, to hypothesise a role for the dorsal fin loop region in differential 23 
ATP potency, and describe novel, testable binding conformations for both the semi-selective 24 
synthetic PβX7 agonist β’-(γ’)-O-(4-benzoyl)benzoyl ATP (BzATP), and the P2X4-selective positive 25 
allosteric modulator ivermectin. We find that the distal benzoyl group of BzATP lies in close 26 
proximity to Lys-127, a residue previously implicated in BzATP binding to P2X7, potentially 27 
explaining the increased potency of BzATP at rat P2X7 receptors. Furthermore, to our knowledge, 28 
we present the first molecular docking of ivermectin to rat P2X4 receptors, illustrating a plausible 29 
binding conformation between the first and second transmembrane domains which not only tallies 30 
with previous mutagenesis studies, but would also likely have the effect of stabilizing the open 31 
channel structure, consistent with the mode of action of this positive allosteric modulator. From our 32 
docking simulations and analysis of sequence homology we propose a series of mutations likely to 33 
confer ivermectin sensitivity to human P2X1. 34 
1 Introduction 35 
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In recent years, our understanding of the relationship between the structure and the function of the 36 
ATP-gated P2X receptor family of ion channels has been transformed by a series of crystal 37 
structures, from the first structure of a P2X receptor, that of Danio rerio P2X4.1 (zfP2X4) in the apo-38 
state, published in 2009 (Kawate et al., 2009), via structures of zfP2X4 bound to ATP (Hattori & 39 
Gouaux, 2012), a Gulf Coast tick (Amblyomma maculatum) P2X structure (Kasuya et al., 2016), 40 
human P2X3 in the apo-, ATP- and antagonist-bound states (Mansoor et al., 2016), zfP2X4 bound to 41 
the partial agonist CTP (Kasuya et al., 2017a), to the most recently determined structures of giant 42 
panda (Ailuropoda melanoleuca) P2X7 (Karasawa & Kawate, 2016) and chicken P2X7 (Kasuya et 43 
al., 2017b). These impressive achievements, along with their enabling of the interpretation of a large 44 
body of prior mutagenesis data (reviewed in (Kawate, 2017; Habermacher et al., 2016; Grimes & 45 
Young, 2015; Samways et al., 2014; Alves et al., 2014; Jiang et al., 2013; Chataigneau et al., 2013)), 46 
have led to significant breakthroughs in our understanding of channel architecture, ligand binding, 47 
and the mechanisms of channel opening, desensitization and both orthosteric and allosteric 48 
antagonism. In addition, the availability of structural data has allowed for the construction and testing 49 
of molecular models of those human receptors which still lack direct high-resolution structural data 50 
(Alves et al., 2014; Fryatt et al., 2016; Caseley et al., 2016; Farmer et al., 2015; Caseley et al., 2015; 51 
Ahmadi et al., 2015), paving the way for mutational analysis to elucidate antagonist binding sites 52 
(Farmer et al., 2015; Allsopp et al., 2017), and structure-aided drug design (Caseley et al., 2016; 53 
Caseley et al., 2015; Ahmadi et al., 2015). 54 
P2X receptors play wide-ranging physiological roles and are important in health and disease 55 
progression (North, 2016); for this reason they have been significant targets for the pharmaceutical 56 
industry (Burnstock, 2017). The functional unit of the P2X receptor is a trimer, and seven P2X 57 
receptor subtypes are found in mammals (numbered P2X1-P2X7), which can form a variety of both 58 
homo-and hetero-trimeric receptors, which display subtly different pharmacological properties and 59 
tissue distribution (North, 2016). Developing potent, subtype-selective P2X receptor modulators has 60 
been a slow process, but several such compounds are now available (Burnstock, 2017; Bartlett et al., 61 
2014), including the P2X7 antagonists CE-224,535 (Stock et al., 2012) and AZD9056 (Eser et al., 62 
2015; Keystone et al., 2012; McInnes et al., 2007), and the P2X3 antagonist AF-219 (Abdulqawi et 63 
al., 2015), which have been used in clinical trials for rheumatoid arthritis, Crohn’s disease and 64 
chronic cough respectively. The majority of developed compounds are antagonists; at present there 65 
are no truly subtype-selective P2X receptor agonists available, although α,ȕ-methylene ATP shows 66 
selectivity for P2X1 and P2X3 receptors, and BzATP is partially selective for P2X7 receptors (North, 67 
2002). One compound, the anti-helminthic drug ivermectin, has also been reported to be a selective 68 
(in terms of P2X receptors) positive allosteric modulator of P2X4 receptors (Khakh et al., 1999). For 69 
the majority of known P2X modulators, their binding sites have not yet been elucidated. However, 70 
the recent crystal structures of human P2X3 in complex with the orthosteric antagonists A-317491 71 
and trinitrophenyl-ATP (TNP-ATP) (Mansoor et al., 2016), chicken P2X7 in complex with TNP-72 
ATP (Kasuya et al., 2017b), and panda P2X7 in complex with a series of allosteric antagonists 73 
including A-740003 (Karasawa & Kawate, 2016) have given valuable insight into the binding modes 74 
and mechanism of antagonism of these compounds. 75 
In this article our aim is to describe our current understanding of small-molecule modulator binding 76 
to P2X receptors, and use this data in conjunction with molecular docking experiments to develop 77 
novel hypotheses for the involvement of the dorsal fin region in altered agonist potency at P2X7 78 
receptors, and how the P2X7-selective agonist BzATP and the P2X4 positive allosteric modulator 79 
ivermectin bind to their respective receptor subtypes. We first focus on the currently available crystal 80 
structures of P2X receptors, highlighting which portions of the receptor they cover, and how they are 81 
related by amino-acid sequence identity. We briefly discuss the conformational changes induced by 82 
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ATP binding, before analyzing the orthosteric binding sites in zfP2X4, human P2X3, gulf coast tick 83 
P2X and chicken P2X7, and the allosteric binding site in panda P2X7. Finally, we build upon 84 
published data from structure-function experiments, using molecular docking simulations to 85 
hypothesise how the P2X7 agonist BzATP may be able to bind more effectively than ATP at the rat 86 
isoform of this receptor by interacting with Lys-127 adjacent to the ATP binding pocket, and how 87 
ivermectin may stabilize the open state of rat P2X4 receptors by binding between the first and second 88 
transmembrane domains. 89 
2 Modulator binding in P2X receptor crystal structures 90 
2.1 Analysis of solved P2X structures 91 
To date, high-resolution structural data has been obtained for a total of six different P2X receptor 92 
constructs, including an NMR structure of the isolated head domain of rat P2X4 (Igawa et al., 2015), 93 
and crystal structures of zfP2X4 (Kawate et al., 2009; Hattori & Gouaux, 2012; Kasuya et al., 94 
2017a), Gulf Coast tick P2X (Kasuya et al., 2016), human P2X3 (Mansoor et al., 2016), panda P2X7 95 
(Karasawa & Kawate, 2016) and chicken P2X7 (Kasuya et al., 2017b). Each available entry in the 96 
Protein Data Bank is listed in Table 1, along with the state in which the crystal structure was 97 
determined and its reported resolution. It is important to note that none of these structures represents 98 
the native, full-length receptor; the regions of protein sequence encompassed by each representative 99 
structure are shown in comparison to the full-length human P2X receptors in Figure 1A, and the 100 
percentage sequence coverage compared to each human P2X receptor shown in Figure 1B. All 101 
‘crystal constructs’ are truncated to some degree at both the N- and C-termini (and indeed the N- and 102 
C-termini of the crystal constructs are often not observed in the crystal structures due to their inherent 103 
flexibility), and all (apart from human P2X3) bear point mutations. The effects of these truncations 104 
and/or mutations on protein function are significant in some cases; the original zfP2X4 apo-state 105 
crystal structure was significantly impaired in ion channel function (Kawate et al., 2009; Young, 106 
2010), the Gulf Coast tick P2X construct, while still able to bind ATP, did not form a functional ion 107 
channel (Kasuya et al., 2016), and the chicken P2X7 construct, while still able to bind TNP-ATP, 108 
was also non-functional (Kasuya et al., 2017b). However, later zfP2X4 constructs (used to elucidate 109 
new apo-state and ATP-bound state structures) displayed channel function approaching that of the 110 
native receptor (Hattori & Gouaux, 2012), and human P2X3 constructs were fully functional 111 
compared to wild-type receptors (Mansoor et al., 2016). The amino-acid sequence identities between 112 
the full-length human P2X receptors and the crystal constructs (Figure 1C) demonstrate that these 113 
structures are very useful as templates for homology modelling with the human receptors that lack 114 
crystal structures, due to the high degree of similarity between them. 115 
2.2 The conformational change induced by ATP binding  116 
The conformational changes induced by the binding of ATP (and the partial agonist CTP) have been 117 
captured in the crystal structures of zfP2X4 (Hattori & Gouaux, 2012; Kasuya et al., 2017a) and 118 
human P2X3 (Mansoor et al., 2016). These changes are vital for the agonist-induced gating of the 119 
cation channel, and while not central to the focus of this article, are discussed briefly here. For a 120 
detailed treatment of the structural basis for the activation of P2X receptors see (Kawate, 2017). 121 
Using the apo- and ATP-bound zfP2X4 crystal structures as a guide (Hattori & Gouaux, 2012), ATP 122 
binding into its pocket in a cleft between subunits (Figure 2, center panel) induces movements in the 123 
extracellular domain of the receptor (Figure 2, right panel), leading to the upward movement of the 124 
dorsal fin domain and the closure of the head region around the ATP binding site, and the downward 125 
movement of the left flipper domain. This in turn leads to movement in the lower body of the 126 
extracellular domain, which has the effect of moving the second transmembrane domain (which lines 127 
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the channel) relative to the first transmembrane domain (Figure 2, left panel), opening the channel in 128 
a manner similar to a camera iris. In the recent ATP-bound human P2X3 crystal structure (Mansoor 129 
et al., 2016), the center of the second transmembrane domain is observed to transition from an α-130 
helix to a 310 helix, which may stabilize channel opening. 131 
2.3 The orthosteric binding site 132 
Prior to the availability of P2X receptor crystal structures complexed with ATP, several conserved 133 
amino-acids critical for ligand binding were identified in a series of key structure-function 134 
experiments (reviewed in (Young, 2010; Browne et al., 2010)), and these residues were demonstrated 135 
to line a pocket between receptor subunits in the extracellular domain in the first P2X crystal 136 
structure, apo-zfP2X4 (Kawate et al., 2009). ATP-bound structures are now available for zfP2X4 137 
(Hattori & Gouaux, 2012), Gulf Coast tick P2X (Kasuya et al., 2016) and human P2X3 (also 138 
obtained in the presence of the agonist 2-methylthio-ATP (Mansoor et al., 2016) (Figure 3 A, B, C, 139 
D); they display near-identical U-shaped conformations. Of critical importance for agonist activity 140 
are the polar interactions with the Ȗ-phosphate and the adenine ring; P2X receptors are not activated 141 
by ADP (although tethering of ligands to one binding site of P2X7 has been shown to alter the 142 
specificity of other binding sites in the same receptor, enabling further activation by ADP and CTP 143 
(Browne & North, 2013)). P2X receptors display selectivity for purines over pyrimidines, but CTP is 144 
a partial agonist at some P2X receptors, including zfP2X4 (Kasuya et al., 2017a). In the crystal 145 
structure of CTP-bound zfP2X4 (Figure 3E), a hydrogen bond is observed between the N-4 atom of 146 
cytosine and the main chain of Thr-189 (zfP2X4 numbering), and an additional hydrogen bond is 147 
formed between the O-2 atom of the cytosine ring and the sidechain of Arg-143. This enables the 148 
CTP to adopt a similar conformation to that of ATP, even though the pyrimidine ring is smaller. 149 
Another point of note in all 5 agonist-bound structures is the close proximity between the Ȗ-150 
phosphate oxygen and the β’-hydroxyl group of the ribose, which may give rise to hydrogen-bond 151 
formation. This hydrogen bond may be very important for maintaining the stability of the ATP 152 
molecule in the P2X receptor orthosteric binding site, as suggested by recent molecular dynamics 153 
simulations and the observation that β’-deoxy-ATP is a poor agonist at human P2X1 receptors in 154 
contrast to γ’-deoxy-ATP (Fryatt et al., 2016). Structures of human P2X3 determined in complex 155 
with the orthosteric antagonists TNP-ATP (Figure 3G) and A-317491 (Figure 3H) (Mansoor et al., 156 
2016), and chicken P2X7 in complex with TNP-ATP (Figure 3F) (Kasuya et al., 2017b) give a 157 
fascinating insight into the molecular basis for competitive antagonism at these receptors. Somewhat 158 
surprisingly, when bound to human P2X3 TNP-ATP adopts a strikingly different conformation to 159 
that of ATP; although the Ȗ-phosphate is in a broadly similar position, the molecule adopts a Y-160 
shaped conformation, making a hydrophobic interaction deep in the cleft between subunits that ATP 161 
does not access (Figure 3G). This Y-shaped conformation and deeper binding is also observed for A-162 
317419 (Figure 3H), and the effect is to prevent the upward movement of the dorsal fin domain, 163 
precluding the closure of the binding cleft that is a prerequisite for channel opening (Mansoor et al., 164 
2016). In chicken P2X7, the TNP-ATP conformation is markedly different to that observed in human 165 
P2X3 (Figure 3F). The adenine ring and ribose adopt similar conformations to that observed for ATP 166 
in other P2X receptor crystal structure, but the position of the TNP moiety is altered (contacting the 167 
head and dorsal fin domains, rather than buried in the body domain as observed in human P2X3), and 168 
the phosphate chains display an extended conformation (Kasuya et al., 2017b). Kasuya et al used 169 
molecular dynamics simulations to conclude that, while TNP-ATP binding to chicken P2X7 induces 170 
initial conformational changes similar to those which might be expected for ATP, the TNP moiety 171 
prevents downward movement of the head domain induced by cleft closure of the ATP binding 172 
pocket and consequently prevents activation of the receptor (Kasuya et al., 2017b). We propose that 173 
the observation of different binding conformations for TNP-ATP in P2X3 and P2X7 subtypes may 174 
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well reflect the 1000-fold difference in potency of TNP-ATP at P2X3 and P2X7 receptors (IC50 ~ 1 175 
nM for P2X3 (North, 2002) and 3.55 µM for chicken P2X7 (Kasuya et al., 2017b)), suggesting that a 176 
competitive antagonist which can bind deeper into the cleft between subunits may well be 177 
significantly more potent than one which prevents movement of the head domain. 178 
2.4 An allosteric binding site in P2X7 179 
The P2X7 receptor, with its wide-ranging proposed physiological roles in inflammatory disease, 180 
cancer, neurological disorders (Bartlett et al., 2014; Pevarello et al., 2017; Roger et al., 2015) and, 181 
most recently, metabolic disease (Arguin et al., 2017), has been a focus within the pharmaceutical 182 
industry and several potent and selective P2X7 antagonists have been developed (Park & Kim, 2017). 183 
Many of these were thought to be orthosteric, but painstaking and elegant recent work by Alsopp  et 184 
al, using structure-function and molecular modelling (Allsopp et al., 2017), and by Karasawa and 185 
Kawate, using functional assay and crystallization of giant panda P2X7 in complex with a series of 186 
P2X7 antagonists (Karasawa & Kawate, 2016) has clearly demonstrated that these compounds bind 187 
to an allosteric site in the extracellular domain distinct from the ATP binding pocket (Figure 4A). 188 
Crystals were obtained in complex with AZ10606120, GW791343, JNJ47965567, A740003 and 189 
A804598 (Figure 4B-F). Comparison of the binding of these compounds shows either an elongated 190 
conformation which appears to extend across subunits (AZ10606120, GW791343, JNJ47965567), or 191 
a more compact conformation making a polar interaction between A740003 and A804598 and the 192 
side-chain of Lys-110. In all cases extensive hydrophobic interactions are observed in a pocket 193 
delineated by Phe-95, Phe-103, Met-105, Phe-293 and Tyr-295 (panda P2X7 numbering). The 194 
discovery of this new allosteric binding pocket in P2X7 (and the availability of the crystal structure 195 
as a modelling template) should greatly facilitate the structure-aided design of new allosteric P2X7 196 
antagonists; it may also be possible to exploit this pocket in other receptor subtypes to develop 197 
antagonists with increased subtype selectivity. 198 
2.5 Comparison of the dorsal fin loops in P2X3, P2X4 and P2X7 199 
P2X receptor subtypes display substantial differences in relative ATP potency. For example, ATP 200 
EC50 values for human P2X3, human P2X4 and human P2X7 have been reported as 0.13 µM, 7.4 µM 201 
and 720 µM (in low divalent cation-containing solution) respectively (Garcia-Guzman et al., 1997; 202 
Neelands et al., 2003; Stokes et al., 2006). Particularly striking is the >1000-fold lower ATP potency 203 
observed at P2X7 receptors compared to other subtypes. Lower potency could be either due to 204 
reduced agonist affinity, or reduced ability of the agonist to effect a response (efficacy, here 205 
considered as the ability of the agonist to induce a conformational change in the receptor). Because 206 
the residues important for binding ATP in P2X receptors and the overall shape of the ATP binding 207 
pocket are well-conserved across subtypes, we hypothesize that lower ATP potency observed at 208 
P2X7 receptors may result from reduced efficacy. There are a number of regions of sequence 209 
difference between P2X7 and the other subtypes which could be responsible for differences in 210 
efficacy, but multiple sequence alignment of receptor subtypes shows a clear candidate; the dorsal fin 211 
loop (Figure 5A). This loop moves upward on ATP binding (Hattori & Gouaux, 2012; Mansoor et 212 
al., 2016), and P2X7 subtypes bear a 4 amino-acid deletion in this region, substantially changing its 213 
conformation in P2X7 compared to P2X3 and P2X4, both in complex with ATP (Figure 5B) and 214 
TNP-ATP (Figure 5C). It is interesting to note that while the dorsal fin conformation in human P2X3 215 
bound to ATP and TNP-ATP is markedly different (compare Figures 5B and 5C), suggesting a lack 216 
of movement of the dorsal fin in the antagonist-bound structure, the conformation of this region in 217 
P2X7 is less affected. One reason for this may be that, in chick P2X7, TNP-ATP adopts a similar 218 
conformation to ATP, and so a conformational change in the dorsal fin region has taken place in this 219 
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structure (unfortunately the corresponding apo-structure is not available for comparison). An 220 
alternative hypothesis is that the shorter dorsal fin loop in P2X7 does not undergo the extensive 221 
conformational change seen in P2X3, effectively limiting the degree of conformational change that 222 
occurs in P2X7 upon ATP binding, and thus lowering the efficacy of ATP. One way to test this 223 
hypothesis would be to replace the dorsal fin loop region in P2X7 with that of another subtype (and 224 
vice versa) and testing the effects of this substitution on ATP EC50. It should be noted that the 225 
conformation of the dorsal fin region of each crystal structure may be affected by crystal contacts in 226 
the unit cell of the crystals used for structure determination, and also that these regions of the protein 227 
are likely to be dynamic and mobile, and may be capable of adopting a range of conformations in 228 
either apo- or ligand-bound states. 229 
3 Modelling modulator binding 230 
3.1 The semi-selective P2X7 agonist BzATP 231 
BzATP is a synthetic ATP derivative with a benzoylbenzoyl moiety linked to either the β’ or the γ’ 232 
oxygen of ribose. Commercially available BzATP preparations are a mixture of the two isomers and 233 
to our knowledge, it is not known whether just one or both isomers have activity at P2X7 receptors. 234 
Some initial studies describe the application of the γ’ isomer, but this may be because the original 235 
paper describing BzATP synthesis reported it as the γ’ isomer (Williams & Coleman, 1982). 236 
However, later synthesis and characterization using similar methods reported a mixture of γ’ and β’ 237 
isomers in a 60:40 ratio (Mahmood et al., 1987). BzATP is more potent than ATP at the P2X7 238 
receptor, and this attribute can be used as pharmacological evidence to support functional expression 239 
of P2X7 receptors. However, it is important to note that BzATP is also a full agonist at P2Y receptors 240 
(Boyer & Harden, 1989), a partial agonist at P2X4 receptors (Bowler et al., 2003), and an agonist at 241 
P2X1, P2X2 and P2X5 receptors (Bo et al., 2003; Evans et al., 1995), meaning that claims of 242 
physiological roles for P2X7 receptors based on BzATP-induced responses must be treated with 243 
some caution. However, at P2X7 receptors, BzATP is significantly more potent than ATP 244 
(approximately 30-fold at rat P2X7 compared to 4-fold at mouse P2X7 (Young et al., 2007)) and 245 
elicits larger whole-cell responses (Surprenant et al., 1996). It has previously been demonstrated that 246 
BzATP potency in rat P2X7 is governed by Lys-127 (the mutation A127K in mouse P2X7 247 
significantly increases BzATP potency relative to ATP), and suggested that the side-chain of this 248 
residue might be able to form a π-cation interaction with one of the benzene rings of BzATP (Young 249 
et al., 2007). To test this hypothesis, we docked both isomers of BzATP into the ATP binding site of 250 
a molecular model of mouse P2X7 bearing the A127K mutation (Figure 6). Docking of β’-BzATP 251 
reproduced a strikingly similar conformation to that of ATP (Figure 6A). Approximate positions of 252 
the phosphate chains and adenine moiety were preserved; however the ribose of BzATP was 253 
translated relative to ATP, presumably to accommodate the benzoylbenzoyl moiety. Docking of γ’-254 
BzATP (Figure 6B) was less satisfactory; although the positions of the adenine and ribose were well-255 
conserved, the position of the critical Ȗ-phosphate was not. Strikingly, in both conformations, the 256 
benzene ring most distant from the ribose was positioned very near to Lys-127, suggesting that 257 
formation of a π-cation interaction is plausible. In summary, our docking suggests not only that the 258 
original molecular hypothesis for enhanced BzATP potency at rat P2X7 (Young et al., 2007) may be 259 
correct, but also that the β’ isomer of BzATP should possess greater activity at PβX7 receptors than 260 
the γ’ isomer. Testing this hypothesis would require the selective purification of β’- and γ’-BzATP 261 
isomers. 262 
3.2 The P2X4 positive allosteric modulator ivermectin 263 
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P2X4 receptors play an important role in the central nervous system (CNS) in the modulation of 264 
neuroinflammation and neuropathic pain, and are important CNS drug targets (Stokes et al., 2017). 265 
Ivermectin (Figure 7A) is an anti-helminthic drug used in veterinary medicine, and in humans to treat 266 
river blindness (onchocerciasis) (Zemkova et al., 2014). It kills nematodes by activating glutamate-267 
gated chloride channels and has been shown to affect the activity of several other ligand-gated ion 268 
channels, including glycine receptors, Ȗ-amino butyric acid (GABA) receptors, nicotinic 269 
acetylcholine receptors and P2X4 receptors (Zemkova et al., 2014; Chen & Kubo, 2017). The mode 270 
of action of ivermectin on the cys-loop ligand-gated ion channel family has been structurally 271 
characterised; ivermectin is known to bind between transmembrane domains, stabilising the channel 272 
open state (Hibbs & Gouaux, 2011). In this way ivermectin acts as a positive allosteric modulator. It 273 
is currently unknown how ivermectin binds to P2X4 receptors, but it is known that ivermectin exerts 274 
two effects on P2X4;  it causes an increase in maximum current amplitude (this effect occurs at 275 
relatively low concentrations of ivermectin and has an EC50 of 0.β5 μM), and at it slows receptor 276 
deactivation by stabilizing the open conformation of the channel (this effect occurs at relatively high 277 
concentrations of ivermectin and has an EC50 of 2 µM) (Priel & Silberberg, 2004). The dual effects 278 
of ivermectin potentially suggest two (or more) binding modes, but it is plausible to assume that it 279 
may stabilise the open conformation of P2X4 by a similar mechanism to that observed in cys-loop 280 
receptors. Indeed, a series of mutagenesis and structure-function experiments have been conducted in 281 
order to determine amino-acid residues important for the effects of ivermectin at P2X4 receptors 282 
(Samways et al., 2012; Silberberg et al., 2007; Tvrdonova et al., 2014), reviewed in (Chen & Kubo, 283 
2017) and the majority of these residues are clustered towards the upper (extracellular side of the 284 
membrane) and central portions of the first transmembrane domain, and the central and lower 285 
portions of the second transmembrane domain (Figure 7B). Using these amino-acids as a reference, 286 
we were able to dock ivermectin B1a into a molecular model of rat P2X4 between the first and 287 
second transmembrane domains from adjacent subunits (Figure 7B). In our docking simulation the 288 
ivermectin molecule is positioned with the hydrogenated benzofuran moiety towards the intracellular 289 
face of the membrane, forming hydrophobic interactions with Leu-345 and Val-348 near the bottom 290 
of the second transmembrane domain of one subunit (colored blue in Figure 7C, D). The disaccharide 291 
moiety (dioleandrose) is positioned near the extracellular face, forming hydrophobic interactions with 292 
Tyr-42, Trp-46 and Val-47 at the top of the first transmembrane domain, and a hydrogen bond 293 
between the hydroxyl group of the distal oleandrose and the oxygen atom of the side-chain of Asn-294 
338 near the top of the second transmembrane domain of the adjacent subunit (colored green in 295 
Figure 7C, D). This means that ivermectin is interacting with the bottom of the second 296 
transmembrane domain in one subunit, and the top of both the first and second transmembrane 297 
domains in the adjacent subunit, which would have the effect of stabilising the channel in the open 298 
state following activation by ATP. It is important to note that this conformation does not preclude 299 
ivermectin from binding to the other two equivalent binding sites in the trimer. 300 
In order to understand why ivermectin is capable of potentiating current responses at some P2X 301 
receptor subtypes but not others, we aligned the transmembrane domain sequences of human, rat and 302 
mouse P2X1, P2X1, P2X3, P2X4 and P2X7, along with those of Schistosoma mansoni P2X (Agboh 303 
et al., 2004) and Hypsibius dujardini P2X (Bavan et al., 2009), also shown to be sensitive to 304 
ivermectin (Figure 7E). The ivermectin-sensitive receptor subtypes are grouped together in a yellow 305 
box (Figure 7E). It should be noted that ivermectin sensitivity has been reported in human P2X7 (but 306 
not mouse P2X7) in whole-cell patch clap experiments on transfected human cells (Norenberg et al., 307 
2012); however a recent study on human P2X7 expressed in Xenopus oocytes observed no 308 
potentiation (Schneider et al., 2017). In Figure 7E, amino-acid residues identical to rat P2X4 are 309 
colored in gray, amino-acids conserved across all subtypes are in gray boxes, and amino-acids 310 
conserved in subtypes where ivermectin is active are shown in blue. Red boxes highlight the amino-311 
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acid residues where substitution with tryptophan significantly reduced ivermectin activity in rat P2X4 312 
(Silberberg et al., 2007). Of the nine amino-acids implicated in ivermectin action by tryptophan 313 
mutagenesis, seven are within 4.5Å of the ivermectin molecule in our dock (green and blue arrows 314 
indicate residues in close proximity in Figure 7E), showing a good correlation between our docking 315 
simulation and experimental data. In our docking simulation we observed a hydrogen bond between 316 
the sidechain of Asn-338 and the oleandrose moiety of ivermectin (Figure 7 C,D, large blue 317 
arrowhead in Figure 7E). Interestingly, the rat P2X4 mutant N338W retained ivermectin sensitivity 318 
(Silberberg et al., 2007). We explored this by modelling ivermectin binding to the rat P2X4 N338W 319 
mutant, finding that ivermectin was still able to make an H-arene interaction with the tryptophan 320 
(data not shown). We hypothesise that mutating this residue to one incapable of forming H-bonds 321 
(such as Ile or Leu) should significantly impair the ability of ivermectin to potentiate current 322 
responses at rat P2X4. Analysis of sequence conservation across the transmembrane domains 323 
suggests that the P2X1 subtype is most similar to the ivermectin-sensitive subtypes. While it may not 324 
be possible to confer ivermectin sensitivity to another subtype with one point mutation, we suggest 325 
that a combination of the mutations F33N, T333I, T334N, I341L and F342L in human P2X1 may 326 
confer ivermectin sensitivity to this receptor subtype. 327 
In summary, our docking simulation explains the ability of ivermectin to stabilize the open state of 328 
P2X4 receptors, and hints at the amino-acid residues important for the subtype-specific effects of 329 
ivermectin; furthermore, our docking should permit the rational design of smaller lipophilic 330 
molecules which specifically target sub-regions of the putative ivermectin binding site in P2X4. It is 331 
important to note that Glu-51, located in the lateral ion-access portal just above the transmembrane 332 
domains and conserved in P2X1 and P2X3 receptors (shown in Figure 7E), has also been implicated 333 
in the action of ivermectin (Samways et al., 2012). We did not observe an interaction between 334 
ivermectin and Glu-51 in our docking simulation; it is possible that the region including and 335 
surrounding Glu-51 may contribute to a second ivermectin binding site, which may explain the dual 336 
actions of ivermectin on P2X4 receptors. 337 
4 Concluding Remarks 338 
This article demonstrates how the growing collection of P2X receptor crystal structures, from 339 
different species and subtypes, in complex with orthosteric agonists and both orthosteric and 340 
allosteric antagonists, has not only transformed our understanding of how small molecule modulators 341 
bind to and influence P2X receptor function, but also has enabled us to effectively model novel 342 
binding conformations for other ligands based on the available molecular evidence. We have been 343 
able to compare the binding of ATP at zfP2X4, Gulf Coast tick P2X and human P2X3, and to 344 
analyze the molecular basis for competitive and non-competitive antagonism at human P2X3 and 345 
panda and chicken P2X7. The orthosteric antagonist binding site in P2X7 may well be a valid target 346 
for future structure-based drug design in other receptor subtypes in order to develop subtype-selective 347 
antagonists. We have analyzed the difference in conformation of the dorsal fin loop between P2X7 348 
and P2X3 and P2X4, hypothesizing that the shorter loop in P2X7 may affect the degree of 349 
conformational change induced by ATP binding, and hence the efficacy of the agonist. Using 350 
molecular modeling and docking experiments, we have been able to propose plausible and testable 351 
binding conformations for the agonist BzATP at P2X7, and the positive allosteric modulator 352 
ivermectin at rat P2X4, hypothesizing that the β’ isomer of BzATP should be more potent than the γ’ 353 
isomer, and outlining a series of mutations which may confer ivermectin sensitivity onto P2X1 354 
receptors. While a comprehensive structural basis for subtype-specific differences in agonist potency 355 
is still lacking, it is to be hoped that structures of P2X1 and P2X2 receptor subtypes, where the 356 
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majority of structure-function studies have been conducted, will be solved in the near future, giving 357 
new insights into ligand binding and a better context to previously published data. 358 
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9 Table 528 
Table 1: List of P2X receptor structures (PDB codes) solved to date. All structures were solved 529 
using X-ray diffraction except 2RUP (marked with *), which was obtained using NMR. n/a refers to 530 
sequences with less than 60 amino acids. 531 
PDB ID Resolution (Å) P2X subtype (Species) State (ligand) 
2BP5 2.8  P2X4 (rat)  n/a 
2RUP *  P2X4 (rat)  n/a 
3H9V 3.1  P2X4 (zebrafish)  apo 
3I5D 3.46  P2X4 (zebrafish)  apo 
4DW0 2.9  P2X4 (zebrafish)  apo 
4DW1 2.8  P2X4 (zebrafish)  bound (ATP) 
5F1C 2.9  P2X (Gulf Coast tick)  bound (ATP) 
5SVJ 2.98  P2X3 (human)  apo 
5SVK 2.77  P2X3 (human)  bound (ATP); open 
5SVL 2.9  P2X3 (human)  bound (ATP); desensitised 
5SVM 3.09  P2X3 (human)  bound (2-methylthio-ATP); desensitised 
5SVP 3.3  P2X3 (human)  bound (2-methylthio-ATP); desensitised 
5SVQ 3.25  P2X3 (human)  bound (TNP-ATP) 
5SVR 3.13  P2X3 (human)  bound (A-317491) 
5SVS 4.03  P2X3 (human)  apo 
5SVT 3.79  P2X3 (human)  apo 
5U1L 3.4  P2X7 (giant panda)  apo 
5U1U 3.6  P2X7 (giant panda)  bound (A740003) 
5U1V 3.4  P2X7 (giant panda)  bound (A804598) 
5U1W 3.5  P2X7 (giant panda)  bound (AZ10606120) 
5U1X 3.2  P2X7 (giant panda)  bound (JNJ47965567) 
5U1Y 3.3  P2X7 (giant panda)  bound (GW791343) 
5U2H 3.9  P2X7 (giant panda)  bound (ATP, A804598) 
5WZY 2.8  P2X4 (zebrafish)  bound (CTP) 
5XW6 3.1  P2X7 (chicken)  bound (TNP-ATP) 
*: NMR structure. 
 532 
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10 Figure Legends 534 
Figure 1: Published P2X receptor constructs; sequence coverage and amino-acid identity. (A) 535 
Graphical representation of coverage of human P2Xs sequence by crystal structures showing aligned 536 
domains. Transmembrane domains (TM) highlighted in yellow; white sections represent gaps. 4DW0 537 
was represented separately to highlight the presence and location of an additional mutation compared 538 
to 4DW1. The graphical representation of 5XW6 (chicken P2X7 structure) is not shown. (B) 539 
Percentage coverage of human P2X receptor sequences by each crystal structure, calculated using 540 
BlastP. (C) Amino-acid identity matrix of human P2X receptor sequences and sequences listed in 541 
Table 1 (values in percentage; blue for lowest identity, red for highest identity, n/a for non-alignable 542 
sequences). Sequences of human P2X (hP2X) receptors were retrieved from UniProt database 543 
(Uniprot IDs: P51575, hP2RX1; Q9UBL9, hP2RX2; P56373, hP2RX3; Q99571, hP2RX4; Q93086, 544 
hP2RX5; O15547, hP2RX6; Q99572, hP2RX7) and aligned with PDB sequences using ClustalW. 545 
Sequences with more than 99.5% identity were grouped together under a single PDB ID for clarity 546 
(e.g. 5SVL with 5SVM and 5SVP; 5SVQ with 5SVJ, 5SVK, 5SVR, 5SVT and 5SVS; 4DW1 with 547 
4DW0 and 3H9V; 5U1U with 5U1L, 5U1V, 5U1W, 5U1X, 5U1Y and 5U2H). 548 
Figure 2: Conformational changes observed in zebrafish crystal structure upon ATP binding. 549 
Structures shown are zfP2X4; PDB IDs: 4DW0 (apo) and 4DW1 (ATP-bound). Arrows show the 550 
trajectories of the backbone rearrangement. The apo-structure is presented in white ribbons while the 551 
ATP-bound structure follows the canonical domain coloring scheme (green, transmembrane 552 
domains; blue, lower and upper body; purple, head domain; orange, dorsal fin; red, right flipper; 553 
yellow, left flipper). Detail of transmembrane region and the ATP-binding pocket are shown in the 554 
left and right panels respectively.  555 
Figure 3: Molecular determinants of orthosteric binding. Crystal structures of zebrafish P2X4 556 
(light yellow ribbon) bound to (A) ATP (PDB ID: 4DW1) and (E) CTP (5WZY). Water molecules 557 
are shown as red dots. (B) Gulf coast tick crystal structure (in light cyan ribbon) in the presence of 558 
ATP (5F1C). Human P2X3 crystal structures (light blue ribbon) bound to (C) ATP (5SVK), (D) 2-559 
methylthio-ATP (5SVP), (G) TNP-ATP (5SVQ) and (H) A317491 (5SVR). (F) Crystal structure of 560 
chicken P2X7 (grey ribbon) in the presence of TNP-ATP (5XW6). H-bond interactions are displayed 561 
with dotted lines. Only residues in close proximity to the ligand are labeled. Note that crystal 562 
structure data relative to the ATP binding site is incomplete in (G) where the loop containing S275 is 563 
missing from the PDB file and in (F) where K65 and S275 (labeled in italics) have missing atoms. 564 
Figures were made using Molecular Operating Environment (MOE). 565 
Figure 4: Allosteric antagonists bound to P2X7. (A) Top view of giant panda P2X7 crystal 566 
structure (PDB ID: 5U1W) bound to AZ10606120 antagonist (blue). ATP (pink) was superposed to 567 
highlight the difference between the location of the allosteric pocket and the ATP-binding site. 568 
Crystal structures of giant panda bound to (B) AZ10606120 (5U1W), (C) GW791343 (5U1Y), (D) 569 
JNJ47965567 (5U1X), (E) A740003 (5U1U) and (F) A804598 (5U1V) showing residues near the 570 
allosteric antagonist colored according to (A). F108 is not labelled for clarity. Figures were made 571 
using MOE. 572 
Figure 5: Comparison of the dorsal fin loop structure in P2X3, P2X4 and P2X7. (A) Sequence 573 
alignment of mouse (m), rat (r) and human (h) P2X receptors with crystal structures bound to either 574 
ATP (hP2X3, 5SVK.A; zfP2X4, 4DW1.A; panda P2X7, 5U2H.B) or TNP-ATP (hP2X3, 5SVQ.A; 575 
chick P2X7, 5XW6.A). For each crystal structure the dorsal fin region is shown in a different color 576 
corresponding to those displayed in panels B and C (blue for hP2X3-ATP, purple for hP2X3-TNP-577 
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ATP, green for zfP2X4-ATP, pink for panda P2X7-ATP and yellow for chick P2X7-TNP-ATP), and 578 
the amino-acid residues at the loop boundaries are shown in dark grey boxes. The conserved disulfide 579 
bond is shown with a line. (B) Comparison of the ATP-bound structures of hP2X3, zfP2X4 and 580 
panda P2X7 with the dorsal fin loop shown in blue, purple and pink respectively. The shorter dorsal 581 
fin region of P2X7 leads to a significantly altered loop conformation which may affect the ability of 582 
the receptor to effect conformational change following ATP binding. (C) Comparison of the TNP-583 
ATP-bound structures of hP2X3 and chick P2X7 with the dorsal fin loop shown in purple and yellow 584 
respectively. The disulfide bond is indicated with grey lines. The dorsal fin loop conformation of 585 
hP2X3 is significantly altered compared to that observed in the ATP-bound structure, suggesting that 586 
the conformational change has not taken place. 587 
Figure 6: Docking of BzATP into mouse P2X7 A127K. A mouse P2X7 homology model (Uniprot 588 
sequence: Q9Z1M0, which was modified to obtain the A127K mutation) was generated using 589 
Molecular Operating Environment (MOE) software (MOE 2014.10; Chemical Computing Group 590 
ULC, 1010 Sherbooke St. West, Suite #910, Montreal, QC, Canada, H3A 2R7, 2018). The sequences 591 
of mouse P2X7 receptor and 5U2H.pdb (chain B; retrieved from RCSB Protein Data Bank 592 
(http://www.rcsb.org)) were aligned and the trimeric system was prepared by adding hydrogens and 593 
calculating partial charges according to the AMBER10:EHT forcefield. The MOE Built-in homology 594 
modeling tool was then used with default settings to make the model, maintaining ATP molecules in 595 
the environment and enabling the induced-fit option. As per default settings, the final model was 596 
refined after the generation of 10 intermediate models. Schrödinger Suite was employed for all the 597 
docking simulations and their preprocessing. In brief, the model was prepared, checked and 598 
parameterized with Protein Preparation Wizard (Schrödinger Suite 2015-1, Protein Preparation 599 
Wizard; Epik, Schrödinger, LLC, New York, NY; Impact, Schrödinger, LLC, New York, NY; Prime, 600 
Schrödinger, LLC, New York, NY). The two isomers of BzATP were built using the MOE Builder 601 
tool then preprocessed with LigPrep (Schrödinger, LLC, New York, NY) employing the OPLS_2005 602 
force field and Epik to generate ionization states at pH 7.0 ± 2.0. Docking of the ligands in the 603 
competitive binding site was performed using Glide extra precision (release 2015-1, Glide, 604 
Schrödinger, LLC, New York, NY) within a box of 38Å3, using superposed ATP as the centroid of 605 
the box. (A) β’-BzATP (green) and (B) γ’-BzATP (lilac) compared to the superposed ATP crystal 606 
conformation (dark gray lines). The surface of the pocket is represented in white, the surface of the 607 
shallow pocket where the Lys-127 residue is located near the benzoyl group is represented in blue. H-608 
bond interactions are shown in dark gray dotted lines, hydrophobic interactions in green dotted lines. 609 
Figure 7: Docking of ivermectin (IVM) in the predicted allosteric binding site of the rat P2X4 610 
homology model. A rat P2X4 homology model (Uniprot sequence: P51577) was built using MOE 611 
with 4DW1 structure as a template and prepared for docking with Protein Preparation Wizard (see 612 
Figure 6). Docking was performed within a box of 35Å3 located at the level of the transmembrane 613 
domain using the coordinates of a previously identified pocket (with Site Finder (MOE)) as the 614 
centroid of the box. (A) Chemical structure of ivermectin B1a, highlighting the dioleandrose 615 
(disaccharide) (salmon), spiroketal (yellow) and hydrogenated benzofuran (purple). (B) Location of 616 
the predicted IVM binding site in rat P2X4. The membrane bilayer is delimited by red lines. IVM 617 
atoms are colored according to (A) while the receptor is represented in ribbons, each color 618 
representing a different subunit. (C) Detail of IVM conformation docked between two subunits, 619 
using the same color scheme as in (A). The residues close to the IVM pose and identified to be 620 
important in IVM activity (see text) are shown and colored according to the receptor subunit. The 621 
surface of the receptor is shown in white; colored areas correspond to the highlighted residues. (D) 622 
180-degree rotation of the IVM pose displayed in (C). The third subunit (yellow in (B)) is omitted for 623 
clarity. E) Sequence alignment of the transmembrane (TM) domains of human (h), rat (r), mouse (m), 624 
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Schistosoma mansoni (Sm), and Hypsibius dujardini (Hd) P2X receptor sequences. Amino-acids 625 
identical to those found in rP2X4 are colored in gray. Receptors sensitive to IVM are shown in a 626 
yellow box, and residues conserved across all subtypes are encapsulated in gray boxes. Residues 627 
colored blue are those which are conserved in P2X receptor subtypes where IVM is active. Residues 628 
in red boxes are those identified by Silberberg et al to significantly reduce IVM activity when 629 
mutated to tryptophan (Silberberg et al., 2007). Blue and green arrows indicate the amino-acid 630 
residues within a distance of 4.5̊ of IVM in our rP2X4-IVM dock; arrows are colored according to 631 
the receptor subunit involved in the interaction (same color scheme as Panel A). The large blue arrow 632 
head indicates Asn-338, which in our docking simulation forms an H-bond with the oleandrose 633 
moiety of IVM.  634 
  P2X modulators 
 
18 This is a provisional file, not the final typeset article 
11 Figures  635 
Figure 1 636 
 637 
C
BA 2BP5 2RUP 3I5D 4DW1 5F1C 5SVL 5SVQ 5U1U 5WZY 5XW6
hP2RX1 n.s. 14 87 83 83 89 89 81 83 78
hP2RX2 n.s. 12 79 69 70 76 76 66 69 70
hP2RX3 n.s. 13 90 82 82 90 90 80 82 76
hP2RX4 2 14 91 87 86 94 94 85 87 73
hP2RX5 n.s. 13 81 72 74 81 81 71 72 69
hP2RX6 n.s. 13 82 73 73 80 80 70 73 72
hP2RX7 n.s. 9 69 56 55 58 58 56 56 59
5F1C 100
hP2RX5 42 100
hP2RX3 42 46 100
5SVL 42 48 99 100
5SVQ 42 47 98 99 100
hP2RX6 42 46 40 42 42 100
hP2RX2 43 42 48 50 51 39 100
hP2RX1 43 44 45 46 46 42 40 100
hP2RX7 37 36 39 40 40 34 36 41 100
5XW6 36 41 35 35 35 36 37 43 52 100
5U1U 38 39 42 42 42 37 40 47 85 46 100
3I5D 45 50 47 47 47 42 48 44 46 46 48 100
5WZY 45 51 48 48 48 43 49 45 48 46 48 99 100
4DW1 45 51 48 48 48 43 49 45 48 46 48 99 100 100
hP2RX4 46 53 47 47 47 45 50 51 46 46 47 61 61 61 100
2BP5 n/a 17 14 33 33 0 0 25 20 n/a n/a n/a n/a n/a 80 100
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Figure 2 638 
 639 
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 648 
hP2X1 PTMTTIGSGIGIFGVATVLCDLLLL 354
rP2X1 PTMTTIGSGIGIFGVATVLCDLLLL 354
mP2X1 PTMTTIGSGIGIFGVATVLCDLLLL 354
hP2X2 PTIINLATALTSVGVGSFLCDWILL 364
rP2X2 PTIINLATALTSIGVGSFLCDWILL 353
mP2X2 PTIINLATALTSIGVGSFLCDWILL 366
hP2X3 PTIISSVAAFTSVGVGTVLCDIILL 344
mP2X3 PTIISSVAAFTSVGVGTVLCDIILL 344
rP2X3 PTIISSVAAFTSVGVGTVLCDIILL 344
hP2X4 PTMINIGSGLALLGMATVLCDIIVL 358
rP2X4 PTMINVGSGLALLGVATVLCDVIVL 358
HdP2X ELAMNLGSGIGLLGIATILCDFLTD 368
SmP2X PLTMNIGSGLALLGLAPTVCDIIAL 359
mP2X4 PTMINVGSGLALLGVATVLCDVIVL 358
hP2X7 QLVVYIGSTLSYFGLAAVFIDFLID 356
mP2X7 QLVVYIGSTLSYFGLATVCIDLLIN 356
rP2X7 QLVVYIGSTLSYFGLATVCIDLIIN 356
hP2X1 VGVIFRLIQLVVLVYVIGWVFLYE 52
rP2X1 VGVIFRLIQLVVLVYVIGWVFVYE 52
mP2X1 VGVIFRLIQLVVLVYVIGWVFVYE 52
hP2X2 LGVLYRAVQLLILLYFVWYVFIVQ 64
rP2X2 LGFVHRMVQLLILLYFVWYVFIVQ 52
mP2X2 LGFVHRMVQLLILLYFVWYVFIVQ 65
hP2X3 IGIINRVVQLLIISYFVGWVFLHE 46
mP2X3 IGIINRAVQLLIISYFVGWVFLHE 46
rP2X3 IGIINRAVQLLIISYFVGWVFLHE 46
hP2X4 VGLMNRAVQLLILAYVIGWVFVWE 51
rP2X4 VGLMNRAVQLLILAYVIGWVFVWE 51
HdP2X LGAINRTVQFLVIGYVIGYIFIYA 64
SmP2X IGVTQRLLQLVILIYVVCWVMIYE 47
mP2X4 VGLMNRVVQLLILAYVIGWVFVWE 51
hP2X7 YGTIKWFFHVIIFSYV-CFALVSD 48
mP2X7 YGTVKWVLHMIVFSYI-SFALVSD 48
rP2X7 YGTIKWILHMTVFSYV-SFALMSD 48
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